86 results match your criteria Transurethral Needle Ablation of the Prostate TUNA


How can we Preserve Sexual Function after Ablative Surgery for Benign Prostatic Hyperplasia?

Curr Drug Targets 2021 ;22(1):4-13

Department of Urology, Martha-Maria Hospital Nuremberg, Nuremberg, Germany.

Our aim was to provide a narrative review regarding the prevalence, the associated pathophysiologic pathways and the potential management methods of sexual dysfunction related to ablative surgical techniques for Benign Prostatic Enlargement (BPE). Men suffering from BPE are at high risk of sexual dysfunction due to the disease itself, comorbidities, and pharmacological/surgical treatments. Transurethral resection of the prostate, as the gold standard treatment option for BPE, has historically been associated with relatively high rates of postoperative sexual dysfunction problems, mainly retrograde ejaculation but also erectile dysfunction. Read More

View Article and Full-Text PDF
January 2021

Is transurethral needle ablation of prostate out of fashion? Outcomes of single session office-based transurethral needle ablation of prostate in patients with symptomatic benign prostatic hyperplasia.

Investig Clin Urol 2019 09 30;60(5):351-358. Epub 2019 Jul 30.

Department of Urology, National University Hospital, National University Health System, Singapore.

Purpose: Transurethral needle ablation (TUNA) is a minimally invasive procedure for the treatment of symptomatic benign prostatic hyperplasia (BPH). Compared to transurethral resection of the prostate (TURP), office-based TUNA is an attractive alternative as it is minimally invasive and avoids general anaesthesia. The aim of this study is to evaluate the efficacy of single session office-based TUNA. Read More

View Article and Full-Text PDF
September 2019

Evaluation of outcome of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia: A 10-year experience.

Urol Ann 2019 Apr-Jun;11(2):198-203

Department of Urology, Faculty of Medicine, Tanta University, Tanta, Egypt.

Aim: The aim of this study is to report our 10-year experience with transurethral needle ablation (TUNA) to evaluate its outcome on long-term basis.

Patients And Methods: A total of 351 patients' records who underwent TUNA procedure for the management of benign prostatic hyperplasia were reviewed. The International Prostate Symptom Score (IPSS) and peak urinary flow rate were evaluated before the procedure, at 3 and 6 months postoperatively, and then yearly for 10 years. Read More

View Article and Full-Text PDF

Prospective short-term evaluation of transurethral needle ablation procedure in an ambulatory setting.

Urol Int 2012 26;89(4):451-6. Epub 2012 Oct 26.

Urology Department, Tenon Hospital, 4 rue de la Chine, Paris Cedex 20, France.

Objective: To assess the results of transurethral needle ablation (TUNA) (Prostiva®, Medtronic, France) performed in an ambulatory setting in men with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH).

Materials And Methods: A multicenter open-label study was conducted. Short-term success was defined by ability to leave the hospital on the evening of the intervention, and absence of rehospitalization due to complications during the first postoperative month. Read More

View Article and Full-Text PDF

Effects of pulsed electromagnetic fields on benign prostate hyperplasia.

Int Urol Nephrol 2011 Dec 3;43(4):955-60. Epub 2011 May 3.

Urological Clinic, University Hospital, Faculty of Medicine, University of Ioannina, Ioannina, Greece.

Introduction: Benign prostate hyperplasia (BPH) has been treated with various types of electromagnetic radiation methods such as transurethral needle ablation (TUNA), interstitial laser therapy (ILC), holmium laser resection (HoLRP). In the present study, the effects of a noninvasive method based on the exposure of patients with BPH to a pulsative EM Field at radiofrequencies have been investigated.

Materials And Methods: Twenty patients with BPH, aging 68-78 years old (y. Read More

View Article and Full-Text PDF
December 2011

[Transurethral needle ablation Prostiva for treating symptomatic benign prostatic hyperplasia: a review].

Prog Urol 2010 Sep 29;20(8):566-71. Epub 2010 Jun 29.

Service d'urologie, hôpital Cochin Port-Royal, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.

Benign prostatic hyperplasia (BPH) is a common disease affecting a large proportion of men older than 50 years. There are multiple treatment options for BPH including medications, minimally invasive options such as transurethral needle ablation (Tuna) and transurethral microwave therapy (TUMT), and more invasive options such as transurethral laser vaporization and transurethral resection of the prostate (TURP). The minimally invasive options induce thermal injury to the BPH adenoma with a lower risk of permanent side effects than TURP. Read More

View Article and Full-Text PDF
September 2010

Durability and retreatment rates of minimal invasive treatments of benign prostatic hyperplasia: a cross-analysis of the literature.

Can J Urol 2010 Aug;17(4):5249-54

Department of Urology, New York University Hospital, New York, New York 10016, USA.

Background: Transurethral resection of the prostate (TURP) has been the gold standard of the treatment of benign prostatic hyperplasia (BPH). In recent years there has been a significant shift in the treatment of BPH and guidelines emphasize minimally invasive surgery as a new treatment option. Minimal invasive technologies (MITs), such as transurethral microwave thermotherapy (TUMT), laser ablations, transurethral needle ablation (TUNA) have emerged as an alternative to the TURP. Read More

View Article and Full-Text PDF

[Prostatic calculi: silent stones].

Actas Urol Esp 2010 Jun;34(6):555-9

Servicio de Urología, Facultad de Medicina de la Universidad de Başkent, Turquía.

Introduction And Objectives: Prostate stones are frequently encountered during transurethral resection of the prostate in urology practice. We aimed to demonstrate the physical and chemical properties of prostate stones. We also aimed to determine possible relationship between inflammation of prostate gland and prostate stones. Read More

View Article and Full-Text PDF

The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review.

Asian J Androl 2010 Jul 17;12(4):500-8. Epub 2010 May 17.

Division of Urology, University of Texas Medical School at Houston, Houston, TX 77030, USA.

A systematic review of randomized controlled trials and cohort studies was conducted to evaluate data for the effects of minimally invasive procedures for treatment of symptomatic benign prostatic hyperplasia (BPH) on male sexual function. The studies searched were trials that enrolled men with symptomatic BPH who were treated with laser surgeries, transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA), transurethral ethanol ablation of the prostate (TEAP) and high-intensity frequency ultrasound (HIFU), in comparison with traditional transurethral resection of the prostate (TURP) or sham operations. A total of 72 studies were identified, of which 33 met the inclusion criteria. Read More

View Article and Full-Text PDF

Minimally invasive surgery in the management of benign prostatic hyperplasia.

Minerva Urol Nefrol 2009 Sep;61(3):269-89

Division of Urology, University of Texas Medical School at Houston, Houston, TX 77030, USA.

Unlabelled: Benign prostatic hyperplasia (BPH) is a chronic and often progressive condition, affecting the majority of men by the seventh decade of life. The historical gold standard has been transurethral resection of prostate (TURP), an effective procedure still associated with risk of bleeding, TUR syndrome, and need for general anesthetic and hospitalization. Minimally Invasive Surgical Techniques aim to address these limitations by offering lower morbidity, reducing hospitalization, and increasing convenience. Read More

View Article and Full-Text PDF
September 2009

Update in minimal invasive therapy in benign prostatic hyperplasia.

Minerva Urol Nefrol 2009 Sep;61(3):257-68

Department of Urology, Canisius Wilhemina Hospital, Nijmegen, The Netherlands.

Last decade several new treatment modalities for minimal invasive therapy of benign prostatic hyperplasia have been developed, both ablative and non-ablative. In this review the authors describe the different techniques and clinical studies of bipolar transurethral resection of the prostate (TURP), transurethral resection in saline (TURis), the different laser therapies for the prostate, transurethral microwave thermotherapy (TUMT), high intensity focused ultrasound (HIFU), transurethral needle ablation (TUNA), hot water induced thermotherapy (WIT), prostatic stents, intraprostatic ethanol injections and botulinum toxin A injections. The different bipolar systems and photoselective vaporisation might replace the ''gold standard'', monopolar TURP, in the near future. Read More

View Article and Full-Text PDF
September 2009

[Two-years follow-up of radiofrequency thermotherapy for urination disorders due to benign prostatic hyperplasia].

Prog Urol 2009 Jul 17;19(7):501-6. Epub 2009 May 17.

Hôpital Sainte-Marguerite, 4, boulevard A.-Laveran, BP 50, 13998 Marseille Armées, France.

Aim: To describe medium-term functional results of Transurethral Needle Ablation (TUNA) to treat symptomatic benign prostatic hyperplasia (BPH) refractory to medical treatment.

Materials And Method: Patients who completed at least 2 years follow-up after TUNA were systematically offered a reevaluation including: Flowmetry, PSA, symptom score (IPSS), satisfaction index visual analogic scale (VAS) and a treatment impact evaluation with a Likert scale (ranging from much worse to much improved).

Results: From December 2002 to January 2007, 45 patients were treated with TUNA under local regional anaesthesia (prostatic block). Read More

View Article and Full-Text PDF

[Treatment of benign prostatic hyperplasia by radiofrequency (TUNA): a monocentric study of 28 cases treated in ambulatory surgery].

Prog Urol 2009 May 18;19(5):327-32. Epub 2008 Dec 18.

Service d'urologie, CHU de Caen, Caen, France.

Aim: To assess the feasibility of ambulatory surgery in the treatment of benign prostatic hyperplasia using radio frequency (TUNA) and evaluate its place in terms of efficiency among other minimally invasive surgical techniques.

Method: Fifty-four patients suffering from benign prostatic hyperplasia and for whom medical treatment was ineffective, were treated with radio frequency between September 2004 and June 2007. Among them, 28 patients, whose average age was 65. Read More

View Article and Full-Text PDF

Characterizing Prostiva RF treatments of the prostate for BPH with gadolinium-enhanced MRI.

ScientificWorldJournal 2009 Jan 18;9:10-6. Epub 2009 Jan 18.

Department of Urology, University of Chile, Santiago, Chile.

Transurethral needle ablation (TUNA) is an accepted and effective therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Prostiva (Medtronic, Shoreview, MN) is the newest-generation device, which includes a new needle design and radio frequency (RF) generator. This device creates temperatures of 120 degrees C and necrotic lesions in less than 2. Read More

View Article and Full-Text PDF
January 2009

Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement.

Health Technol Assess 2008 Nov;12(35):iii, ix-x, 1-146, 169-515

Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK.

Objectives: To determine the clinical effectiveness and cost utility of procedures alternative to TURP (transurethral resection of the prostate) for benign prostatic enlargement (BPE) unresponsive to expectant, non-surgical treatments.

Data Sources: Electronic searches of 13 databases to identify relevant randomised controlled trials (RCTs).

Review Methods: Two reviewers independently assessed study quality and extracted data. Read More

View Article and Full-Text PDF
November 2008

Characterizing TUNA ablative treatments of the prostate for benign hyperplasia with gadolinium-enhanced magnetic resonance imaging.

J Endourol 2007 Nov;21(11):1361-6

Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.

Background And Purpose: Transurethral Needle Ablation of the prostate TUNA has been accepted as an office-based treatment for benign prostatic hyperplasia (BPH) for many years. Clinical outcomes have been reported, but the amount and location of the necrosis produced have yet to be characterized. The necrosis caused by TUNA was evaluated by gadolinium-enhanced magnetic resonance imaging (MRI) of the pelvis. Read More

View Article and Full-Text PDF
November 2007

[Advances in minimally invasive treatment of benign prostatic hyperplasia].

Authors:
Bin Yu Zhong Wang

Zhonghua Nan Ke Xue 2007 Aug;13(8):739-43

Department of Urology, the Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200011, China.

The therapeutic options for benign prostatic hyperplasia (BPH) can be divided into medicinal, surgical and minimally invasive treatments. The minimally invasive treatment of BPH is gradually accepted by more and more urologists for its advantages of less damage, good effect, quick recovery and easy acceptance by patients, which includes transurethral needle ablation of the prostate (TUNA), transurethral microwave therapy (TUMT), photoselective laser vaporization of the prostate (PVP), holmium laser enucleation of the prostate (HOLEP) and so on. This article updates the advances in the minimally invasive treatment. Read More

View Article and Full-Text PDF

[Benign prostatic hyperplasia: surgical treatment].

MMW Fortschr Med 2007 Aug;149(33-34):34-6

Klinik und Poliklinik für Urologie, Klinikum Grosshadern, Ludwig-Maximilians-Universität München.

According to the current treatment algorithm, surgical treatment of benign prostatic syndrome (BPS) is the next step after a pharmacological treatment. In addition to conventional transurethral resection of the prostate (TURP), much interest is shifting towards alternative sugical techniques such as transurethral microwave therapy (TUMT),transurethral needle ablation of the prostate (TUNA) and several laser techniques. Read More

View Article and Full-Text PDF

[Evaluation of radiofrequency (TUNA) in the outpatient treatment of benign prostatic hyperplasia].

Prog Urol 2007 Jun;17(4):824-7

Service d'Urologie du CHU de Caen, Caen, France.

Objective: Evaluating the effectiveness and feasibility of transurethral needle ablation (TUNA) for young patients with symptomatic benign hyperplasia (BPH) in outpatient care.

Material And Methods: From 2004 to 2005, 9 patients (mean age: 59.7 years) were treated with the TUNA device. Read More

View Article and Full-Text PDF

Evidence-based guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary.

Curr Med Res Opin 2007 Jul;23(7):1715-32

Urology Complex Structure, Department of Surgery, Azienda Ospedaliera Santa Maria Nuova, Reggio Emilia, Italy.

Background And Scope: Despite the high prevalence and huge socio-economic impact of benign prostatic hyperplasia (BPH) in Italy, no national guidelines have been produced so far. This is a summary of the first Italian guidelines on the diagnosis and treatment of lower urinary tract symptoms (LUTS) related to uncomplicated BPH, prepared by a multidisciplinary panel under the auspices of the Italian Association of Urologists and introduced in Italy in 2003. An update compiled by the authors is also included. Read More

View Article and Full-Text PDF

Long-term results of three different minimally invasive therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: comparison at a single institute.

Int J Urol 2007 Apr;14(4):326-30

Department of Urology, School of Medicine, Keio University, Tokyo, Japan.

Objective: We analyzed the efficacy and durability of three different minimally invasive therapies (MIT) for lower urinary symptoms performed at a single institution based on a 5-year prospective cohort study.

Methods: The pre- and postoperative evaluation was made in 103 patients with the following three MIT options: (i) transurethral microwave thermotherapy (TUMT, n = 34); (ii) transurethral needle ablation (TUNA, n = 29); and (iii) transrectal high intensity focused ultrasound (HIFU, n = 40).

Results: All three treatments significantly improved the symptom scores up to 2 years after treatment. Read More

View Article and Full-Text PDF

Is the minimally invasive treatment as good as transurethral resection for benign prostatic hyperplasia?

Int Urol Nephrol 2007 2;39(1):161-8. Epub 2007 Mar 2.

Division of Urology, Hospital Israelita Albert Einstein, Unicamp R. Augusta 2347, 3o andar, 01413-000 São Paulo, Brazil.

Despite the development of new technologies, transurethral resection of the prostate (TURP) is still considered the gold standard for surgical treatment of the benign prostate hyperplasia (BPH). In general, new minimally invasive treatments have not demonstrated better outcomes than TURP in evidence based medicine trials published to date, and should be reserved for patients who prefer to avoid surgery, who are unsuitable candidates for surgery or who no longer respond favorably to medication. TUMT and TUNA appears to be more effective than medical therapy but less effective than TURP. Read More

View Article and Full-Text PDF
November 2007

How do I treat and follow my TUNA patients.

World J Urol 2006 Sep 21;24(4):397-404. Epub 2006 Jul 21.

Department of Urology, Erasme Hospital, Brussels University Clinics, 808 route de Lennik, 1070, Brussels, Belgium.

Transurethral needle ablation (TUNA) of the prostate is an alternative treatment for benign prostatic hyperplasia (BPH) generating temperatures around 100 degrees C leading to necrotic lesions inside the prostate. TUNA is a minimally invasive, low morbidity associated, approach that uses radiofrequency energy. The needles are covered by teflon shields that protect the urethra from thermal injury. Read More

View Article and Full-Text PDF
September 2006

Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia.

BMC Urol 2006 Jun 21;6:14. Epub 2006 Jun 21.

Agency for Health Technology Assessment, Ministry of Health & Consumers Affairs, Sinesio Delgado 4, 28029 Madrid, Spain.

Background: Benign prostatic hyperplasia (BPH) constitutes a major clinical problem. Minimally invasive therapies for the treatment of symptomatic BPH include Transurethral Needle Ablation (TUNA), but it is unclear what impact this technique has on the disease and its role among other currently available therapeutic options. The objective of this study is to ascertain the efficacy and safety of TUNA in the treatment of BPH. Read More

View Article and Full-Text PDF

[Benign prostatic syndrome (BPS). Ablative treatments].

Urologe A 2006 Jun;45(6):769-80; quiz 781-2

Urologische Klinik und Poliklinik, Klinikum Grosshadern, Ludwig-Maximilians-Universität, 81377 , München,

Today, the surgical treatment of the benign prostatic syndrome (BPS) often follows a course of drug treatment. Besides conventional transurethral resection of the prostate (TURP), which has represented the standard therapeutic option for decades, and its in part significant modifications ("vaporizing resection"; bipolar resection), much of the interest has shifted to alternative instrumental procedures like transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA) or several laser techniques. By reviewing the current literature, preferably from randomized controlled trials, these different procedures are critically assessed. Read More

View Article and Full-Text PDF

Unequal use of new technologies by race: the use of new prostate surgeries (transurethral needle ablation, transurethral microwave therapy and laser) among elderly Medicare beneficiaries.

J Urol 2006 May;175(5):1830-5; discussion 1835

Division of Health Services Research and Policy, University of Minnesota School of Public Health, Minneapolis, Minnesota 55455, USA.

Purpose: We compared the availability and use of transurethral microwave therapy, transurethral needle ablation, contact or noncontact laser therapy and transurethral resection of the prostate among elderly black and white Medicare beneficiaries.

Materials And Methods: We examined 100% Medicare Inpatient, Outpatient, Carrier and Denominator files of men 65 years old or older who underwent these procedures in 1999 through 2001. White-to-black race rate ratios for each procedure were computed for the entire United States, as well as for a restricted set of counties in which procedures were available to black beneficiaries. Read More

View Article and Full-Text PDF

[Treatment of benign prostatic hyperplasia (BPH) by transurethral needle ablation (TUNA) and 36-month follow-up of the retreatment rate].

Prog Urol 2005 Sep;15(4):674-80

Service d'Urologie, Hôpital Edouard Herriot, Lyon, France.

Objective: Benign prostatic hyperplasia (BPH) is a disease affecting about 25% of men over the age of 40. One half of these men report symptoms that interfere with their daily activities.

Material And Methods: In this multicentre study, 102 patients with BPH were treated by transurethral needle ablation (TUNA). Read More

View Article and Full-Text PDF
September 2005

Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.

Authors:

Ont Health Technol Assess Ser 2006 1;6(17):1-121. Epub 2006 Aug 1.

Objective: The Ontario Health Technology Advisory Committee asked the Medical Advisory Secretariat (MAS) to conduct a health technology assessment on energy delivery systems for the treatment of benign prostatic hyperplasia (BPH).

Clinical Need: TARGET POPULATION AND CONDITION BPH is a noncancerous enlargement of the prostate gland and the most common benign tumour in aging men. (1) It is the most common cause of lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) and is an important cause of diminished quality of life among aging men. Read More

View Article and Full-Text PDF
October 2012

Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer.

Pathol Res Pract 2005 ;201(8-9):593-8

Department of Urology, Dokuz Eylul University School of Medicine, Izmir, Turkey.

The aim of the study was to investigate immunohistochemically the expression of vascular endothelial growth factor (VEGF) in untreated and androgen-deprived patients with prostate cancer. The study included 20 patients with prostate cancer who had undergone transurethral prostatectomy due to infravesical obstruction. All patients had been receiving androgen deprivation therapy for at least 3 months. Read More

View Article and Full-Text PDF
November 2005

[Transurethral ablation (Precision Plus) in the treatment of patients with benign prostatic hyperplasia].

Urologiia 2005 May-Jun(3):12-5

Benign prostatic hyperplasia (BPH) is a common condition among elderly men. Transurethral needle ablation of the prostate (TUNA) is a minimally invasive procedure for treatment of BPH. With TUNA, the inner region of the prostate is selectively ablated with temperatures approaching 90-100 degrees C while prostatic urothelium is preserved. Read More

View Article and Full-Text PDF
September 2005